Adjuvant Therapy and Neoadjuvant Therapy for Melanoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 266

Special Issue Editor


E-Mail Website
Guest Editor
Melanoma Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
Interests: adjuvant therapy; melanoma; clinical trial

Special Issue Information

Dear Colleagues,

Adjuvant therapy and neoadjuvant therapy are two types of treatment used for melanoma, a type of skin cancer. Adjuvant therapy is used after primary treatment, such as surgery, to prevent the cancer from returning. It may involve chemotherapy, radiation therapy, or targeted therapy. Neoadjuvant therapy, on the other hand, is used before primary treatment in order to shrink the tumor and make it easier to remove. This may involve the same types of treatment as adjuvant therapy. Both adjuvant and neoadjuvant therapies have shown promising results in improving survival rates for patients with melanoma. This special issue will highlight clinical research on therapeutic strategies in melanoma.

Dr. Michele Del Vecchio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adjuvant therapy
  • neoadjuvant therapy
  • melanoma
  • skin cancer
  • treatment
  • survival

Published Papers

This special issue is now open for submission.
Back to TopTop